Literature DB >> 16147581

A spectrum of behaviour in silent corticotroph pituitary adenomas.

S E Baldeweg1, J R Pollock, M Powell, J Ahlquist.   

Abstract

Silent corticotroph adenomas (SCA) are pituitary tumours positive on immunohistochemical staining for ACTH but without clinical evidence of Cushing's disease in the patient. Previous reports suggest that these tumours may behave in a more aggressive way then other pituitary adenomas. We have followed the natural history of SCA and assessed whether histopathological indices predict tumour behaviour. We identified 22 patients in whom trans-sphenoidal surgery was performed for a non-functioning adenoma (NFA) with positive immunostaining for ACTH between 1990 and 2000 and examined the history of their disease. Patients were followed up for a mean of 4.8 years. A total of 86.7% of patients had documented visual deficits at presentation. In four cases hypercortisolaemia was observed later in the course of the disease. Two patients died as a result of their SCA and 33.3% of tumours recurred. Recurrence was more frequent in patients treated with adjuvant radiotherapy. Pathological indices (increased mitotic range and Ki-67) did not predict recurrence or malignant transformation. We suggest that certain 'silent' corticotroph tumours may have the potential for ACTH secretion leading to hypercortisolaemia at a later stage in the disease. The possibility of transformation to a more aggressive tumour needs to be considered in all SCA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16147581     DOI: 10.1080/02688690500081230

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  26 in total

Review 1.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

2.  The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.

Authors:  Hiroshi Nishioka; Naoko Inoshita; Ozgur Mete; Sylvia L Asa; Kyohei Hayashi; Akira Takeshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Yasuhiro Takeuchi; Shozo Yamada
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

3.  The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3.

Authors:  Alberto Righi; Marco Faustini-Fustini; Luca Morandi; Valentina Monti; Sofia Asioli; Diego Mazzatenta; Antonella Bacci; Maria Pia Foschini
Journal:  Endocrine       Date:  2016-08-04       Impact factor: 3.633

Review 4.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

5.  Symptomatic cystic degeneration of a clinically silent corticotroph tumor of the pituitary gland.

Authors:  Michael T Walsh; William T Couldwell
Journal:  Skull Base       Date:  2010-09

Review 6.  Silent (clinically nonfunctioning) pituitary adenomas.

Authors:  Sarah E Mayson; Peter J Snyder
Journal:  J Neurooncol       Date:  2014-03-28       Impact factor: 4.130

Review 7.  Prognostic factors of regrowth in nonfunctioning pituitary tumors.

Authors:  Gerald Raverot; Alexandre Vasiljevic; Emmanuel Jouanneau
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

8.  Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up.

Authors:  Kristin Astrid Øystese; Manuela Zucknick; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2017-05-17       Impact factor: 3.633

Review 9.  Modification of hormonal secretion in clinically silent pituitary adenomas.

Authors:  Tania Daems; Johan Verhelst; Alex Michotte; Pascale Abrams; Dirk De Ridder; Roger Abs
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  Absence of immunostaining for growth hormone in a subset of patients with acromegaly.

Authors:  Jason L Schroeder; Alejandro M Spiotta; Maria Fleseriu; Richard A Prayson; Amir H Hamrahian; Robert J Weil
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.